Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo.
BACKGROUND
There is considerable controversy about the degree of acid suppression that is optimal for the treatment of peptic disorders.


OBJECTIVE
To compare the effects of three different regimens that are reported to strongly inhibit acid secretion.


METHODS
Intragastric 24-hour pH monitoring was performed in 11 healthy subjects in a randomized, multiple, cross-over, double-blind study. Each subject received four dose regimens, each for 2 weeks, in a random order. The regimens were: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m., and placebo.


RESULTS
The decrease in gastric acidity during the daytime and during the total 24-hour period by all three treatments was significantly greater than after placebo; a significant difference in acid inhibition was found between ranitidine and 40 mg omeprazole, but not between ranitidine and 20 mg omeprazole, nor between the two doses of omeprazole. During the night-time the decrease in gastric acidity by all three treatments was significantly greater than after placebo; no difference was seen between the two doses of omeprazole and ranitidine. For the time of pH greater than 3 we found no statistical difference between the various acid decreasing regimens. The pH remained significantly longer above 4 after ranitidine and the two doses of omeprazole compared with placebo, and also longer above 4 after 40 mg omeprazole compared with ranitidine, but not after 20 mg omeprazole compared with ranitidine, nor after the two different doses of omeprazole.


CONCLUSIONS
Dosing with 300 mg ranitidine b.d., 20 mg omeprazole or 40 mg omeprazole is superior in gastric acid inhibition compared with placebo, when measured using 24-hour pH monitoring.
Houben
G M
GM
Department of Gastroenterology, Academic Hospital, Maastricht, Netherlands.
Hooi
J
J
Hameeteman
W
W
Stockbrügger
R W
RW
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000494:pharmacology*; D010507:Periodicity; D011899:Ranitidine / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D011899:Ranitidine; D009853:Omeprazole